Document is current
Any future updates will be listed below
-
Authors
Oomen, Patrick G. A. https://orcid.org/0000-0003-0455-7394
Hakkers, Charlotte S.
Arends, Joop E.
van der Berk, Guido E. L.
Pas, Pascal
Hoepelman, Andy I. M.
van Welzen, Berend J. https://orcid.org/0000-0001-5601-4207
du Plessis, Stefan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02308332 at ClinicalTrials.govDocuments that mention this clinical trial
Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial
https://doi.org/10.1007/s40121-024-00966-7
-
Funding
Funding for this research was provided by:
Gilead Sciences
- License Information
-
More Information
Article History
Received: 14 January 2024
Accepted: 25 March 2024
First Online: 20 April 2024
Declarations
:
: Joop E Arends has received advisory board fees from ViiV Healthcare. Berend J van Welzen has received a research grant and speaker fees from Gilead Sciences, has received speaker and advisory board fees from ViiV Healthcare: all fees were paid to the institution. J.A. has changed their affiliation after the completion of the manuscript. His current affiliation is Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht. Berend J. van Welzen is an Editorial Board member of<i> Infectious Diseases and Therapy</i>. Berend J. van Welzen was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. For the remaining authors no conflicts of interest are present to be declared.
: The trial was reviewed and approved by the Medical Research Ethics Committee of the UMC Utrecht, performed in accordance with the Declaration of Helsinki and registered at Clinicaltrials.gov [NCT02308332].
